{
  "claim_id": "claim_005",
  "claim": "Flublok (quadrivalent) was evaluated in the pivotal trial against Fluarix (quadrivalent standard-dose vaccine).",
  "document": "FlublokPI",
  "verified_evidence": [
    {
      "id": 1,
      "quote": "Study 6 (NCT02285998) enrolled subjects 50 years of age and older, randomized to receive Flublok Quadrivalent or Comparator (Fluarix Quadrivalent, manufactured by GlaxoSmithKline) as an active control [see Clinical Studies (14)]. The safety analysis population included 4328 Flublok Quadrivalent recipients and 4344 Comparator vaccine recipients.",
      "supports_claim": true,
      "explanation": "The quote appears on page 3 of the document, with only minor differences in formatting and wording due to OCR cleanup. The document states: 'Study 6 (NCT02285998) enrolled subjects 50 years of age and older, randomized to receive Flublok Quadrivalent or Comparator (Fluarix Quadrivalent, manufactured by GlaxoSmithKline) as an active control [see Clinical Studies (14)]. The safety analysis population included 4328 Flublok Quadrivalent recipients and 4344 Comparator vaccine recipients.' This matches the quoted content in all essential facts, numbers, and technical details.. The quote directly supports the claim. It explicitly states that Study 6 (the pivotal trial) enrolled subjects 50 years and older and randomized them to receive either Flublok Quadrivalent or Fluarix Quadrivalent (a standard-dose vaccine) as an active control. The numbers of recipients for each group are also provided. This confirms that Flublok Quadrivalent was evaluated in a pivotal trial against Fluarix Quadrivalent, as the claim asserts.",
      "presence_explanation": "The quote appears on page 3 of the document, with only minor differences in formatting and wording due to OCR cleanup. The document states: 'Study 6 (NCT02285998) enrolled subjects 50 years of age and older, randomized to receive Flublok Quadrivalent or Comparator (Fluarix Quadrivalent, manufactured by GlaxoSmithKline) as an active control [see Clinical Studies (14)]. The safety analysis population included 4328 Flublok Quadrivalent recipients and 4344 Comparator vaccine recipients.' This matches the quoted content in all essential facts, numbers, and technical details.",
      "support_explanation": "The quote directly supports the claim. It explicitly states that Study 6 (the pivotal trial) enrolled subjects 50 years and older and randomized them to receive either Flublok Quadrivalent or Fluarix Quadrivalent (a standard-dose vaccine) as an active control. The numbers of recipients for each group are also provided. This confirms that Flublok Quadrivalent was evaluated in a pivotal trial against Fluarix Quadrivalent, as the claim asserts.",
      "original_relevance": "This quote explicitly states that Flublok Quadrivalent was evaluated in a trial (Study 6) where it was directly compared against Fluarix Quadrivalent, confirming that the pivotal trial involved these two vaccines."
    },
    {
      "id": 2,
      "quote": "The primary efficacy endpoint of Study 6 was rtPCR-positive, protocol defined ILI due to any strain of influenza. Attack rates and relative vaccine efficacy (rVE), defined as 1 - [Attack rate Flublok Quadrivalent / Attack Rate Comparator], were calculated for the total efficacy population (n=8604) for the primary efficacy endpoint and for several alternative efficacy endpoints (Table 5). Antigenic and phylogenetic evaluations of the similarity (\"matching\") of clinical isolates to vaccine antigens were not performed. CDC epidemiological data for the 2014-2015 influenza season indicated that Influenza A (H3N2) viruses predominated and that most influenza A/H3N2 viruses were antigenically dissimilar while B viruses were antigenically similar to vaccine antigens during the 2014-2015 season. Study 6 met the pre-specified success criterion for the primary endpoint (lower limit of the 2-sided 95% CI of vaccine efficacy for Flublok Quadrivalent relative to Comparator should be not less than 9.1%).",
      "supports_claim": true,
      "explanation": "The quote appears on page 4 of the document, with only minor formatting and wording differences due to OCR cleanup. The content is semantically equivalent. For example, the quote says: 'The primary efficacy endpoint of Study 6 was rtPCR-positive, protocol defined ILI due to any strain of influenza. Attack rates and relative vaccine efficacy (rVE), defined as 1 - [Attack rate Flublok Quadrivalent / Attack Rate Comparator], were calculated for the total efficacy population (n=8604) for the primary efficacy endpoint and for several alternative efficacy endpoints (Table 5). Antigenic and phylogenetic evaluations of the similarity (\"matching\") of clinical isolates to vaccine antigens were not performed. CDC epidemiological data for the 2014-2015 influenza season indicated that Influenza A (H3N2) viruses predominated and that most influenza A/H3N2 viruses were antigenically dissimilar while B viruses were antigenically similar to vaccine antigens during the 2014-2015 season. Study 6 met the pre-specified success criterion for the primary endpoint (lower limit of the 2-sided 95% CI of vaccine efficacy for Flublok Quadrivalent relative to Comparator should be not less than 9.1%).' The document contains this information nearly verbatim, with only minor differences in punctuation and formatting.. The quote directly supports the claim. It explicitly states that Study 6 evaluated Flublok Quadrivalent against a Comparator, and elsewhere on the same page, the Comparator is clearly identified as 'Fluarix Quadrivalent, manufactured by GlaxoSmithKline.' The quote also describes the primary efficacy endpoint and the analysis performed, confirming that the pivotal trial compared Flublok Quadrivalent to Fluarix Quadrivalent. No inference is required; the information is explicit.",
      "presence_explanation": "The quote appears on page 4 of the document, with only minor formatting and wording differences due to OCR cleanup. The content is semantically equivalent. For example, the quote says: 'The primary efficacy endpoint of Study 6 was rtPCR-positive, protocol defined ILI due to any strain of influenza. Attack rates and relative vaccine efficacy (rVE), defined as 1 - [Attack rate Flublok Quadrivalent / Attack Rate Comparator], were calculated for the total efficacy population (n=8604) for the primary efficacy endpoint and for several alternative efficacy endpoints (Table 5). Antigenic and phylogenetic evaluations of the similarity (\"matching\") of clinical isolates to vaccine antigens were not performed. CDC epidemiological data for the 2014-2015 influenza season indicated that Influenza A (H3N2) viruses predominated and that most influenza A/H3N2 viruses were antigenically dissimilar while B viruses were antigenically similar to vaccine antigens during the 2014-2015 season. Study 6 met the pre-specified success criterion for the primary endpoint (lower limit of the 2-sided 95% CI of vaccine efficacy for Flublok Quadrivalent relative to Comparator should be not less than 9.1%).' The document contains this information nearly verbatim, with only minor differences in punctuation and formatting.",
      "support_explanation": "The quote directly supports the claim. It explicitly states that Study 6 evaluated Flublok Quadrivalent against a Comparator, and elsewhere on the same page, the Comparator is clearly identified as 'Fluarix Quadrivalent, manufactured by GlaxoSmithKline.' The quote also describes the primary efficacy endpoint and the analysis performed, confirming that the pivotal trial compared Flublok Quadrivalent to Fluarix Quadrivalent. No inference is required; the information is explicit.",
      "original_relevance": "This quote provides details about the design and analysis of Study 6, confirming that Flublok Quadrivalent was evaluated against a Comparator, which is identified elsewhere as Fluarix Quadrivalent."
    },
    {
      "id": 3,
      "quote": "Abbreviations: rtPCR=reverse transcriptase polymerase chain reaction; Comparator=U.S.-licensed quadrivalent inactivated influenza vaccine, Fluarix Quadrivalent, manufactured by GlaxoSmithKline; n=number of influenza cases; N=number of subjects in treatment group; RR=relative risk (Attack Rate Flublok/Attack Rate IIV4); rVE = [(1-RR) \u00d7 100]. *Study 6 is registered as NCT02285998.",
      "supports_claim": true,
      "explanation": "The quote appears on page 4 of the document, in the section discussing Study 6. The text states: 'Abbreviations: rtPCR=reverse transcriptase polymerase chain reaction; Comparator=U.S.licensed quadrivalent inactivated influenza vaccine, Fluarix Quadrivalent, manufactured by GlaxoSmithKline; n=number of influenza cases; N=number of subjects in treatment group; RR=relative risk (Attack Rate Flublok/Attack Rate IIV4); rVE = [(1-RR) \u00d7 100]. *Study 6 is registered as NCT02285998.' This matches the quote provided, with only minor formatting differences (e.g., 'Quad rival ent' vs 'Quadrivalent' due to OCR artifacts), but all facts, numbers, and technical content are preserved.. The quote explicitly defines the Comparator in Study 6 as 'U.S.-licensed quadrivalent inactivated influenza vaccine, Fluarix Quadrivalent, manufactured by GlaxoSmithKline.' This directly supports the claim that Flublok (quadrivalent) was evaluated in the pivotal trial against Fluarix (quadrivalent standard-dose vaccine). The context and content confirm that the pivotal trial (Study 6) compared Flublok Quadrivalent to Fluarix Quadrivalent.",
      "presence_explanation": "The quote appears on page 4 of the document, in the section discussing Study 6. The text states: 'Abbreviations: rtPCR=reverse transcriptase polymerase chain reaction; Comparator=U.S.licensed quadrivalent inactivated influenza vaccine, Fluarix Quadrivalent, manufactured by GlaxoSmithKline; n=number of influenza cases; N=number of subjects in treatment group; RR=relative risk (Attack Rate Flublok/Attack Rate IIV4); rVE = [(1-RR) \u00d7 100]. *Study 6 is registered as NCT02285998.' This matches the quote provided, with only minor formatting differences (e.g., 'Quad rival ent' vs 'Quadrivalent' due to OCR artifacts), but all facts, numbers, and technical content are preserved.",
      "support_explanation": "The quote explicitly defines the Comparator in Study 6 as 'U.S.-licensed quadrivalent inactivated influenza vaccine, Fluarix Quadrivalent, manufactured by GlaxoSmithKline.' This directly supports the claim that Flublok (quadrivalent) was evaluated in the pivotal trial against Fluarix (quadrivalent standard-dose vaccine). The context and content confirm that the pivotal trial (Study 6) compared Flublok Quadrivalent to Fluarix Quadrivalent.",
      "original_relevance": "This quote explicitly defines the Comparator in Study 6 as Fluarix Quadrivalent, directly supporting the claim that Flublok Quadrivalent was evaluated against Fluarix Quadrivalent in the pivotal trial."
    },
    {
      "id": "comp_1",
      "quote": "The primary efficacy endpoint of Study 6 was rtPCR-positive, protocol defined ILI due to any strain of influenza. Attack rates and relative vaccine efficacy (rVE), defined as 1 [Attack rate Flublok Quadrivalent / Attack Rate Comparator], were calculated for the total efficacy population (n=8604) for the primary efficacy endpoint and for several alternative efficacy endpoints (Table 5).",
      "supports_claim": true,
      "explanation": "The quote appears on page 4 of the document: 'The primary efficacy endpoint of Study 6 was rtPCR-positive, protocol defined ILI due to any strain of influenza. Attack rates and relative vaccine efficacy (rVE), defined as 1 [Attack rate Flublok Quadrivalent / Attack Rate Comparator], were calculated for the total efficacy population (n=8604) for the primary efficacy endpoint and for several alternative efficacy endpoints (Table 5).' The wording and technical content match the quote to verify, with only minor formatting differences (e.g., 'Quad rival ent' vs 'Quadrivalent').. The quote directly describes Study 6, stating that Flublok Quadrivalent was compared to a 'Comparator' and that relative vaccine efficacy was calculated between Flublok Quadrivalent and the Comparator. Additional context in the document (page 3 and 4) explicitly identifies the Comparator as Fluarix Quadrivalent, a standard-dose quadrivalent vaccine. Therefore, the quote genuinely supports the claim that Flublok (quadrivalent) was evaluated in the pivotal trial against Fluarix (quadrivalent standard-dose vaccine).",
      "presence_explanation": "The quote appears on page 4 of the document: 'The primary efficacy endpoint of Study 6 was rtPCR-positive, protocol defined ILI due to any strain of influenza. Attack rates and relative vaccine efficacy (rVE), defined as 1 [Attack rate Flublok Quadrivalent / Attack Rate Comparator], were calculated for the total efficacy population (n=8604) for the primary efficacy endpoint and for several alternative efficacy endpoints (Table 5).' The wording and technical content match the quote to verify, with only minor formatting differences (e.g., 'Quad rival ent' vs 'Quadrivalent').",
      "support_explanation": "The quote directly describes Study 6, stating that Flublok Quadrivalent was compared to a 'Comparator' and that relative vaccine efficacy was calculated between Flublok Quadrivalent and the Comparator. Additional context in the document (page 3 and 4) explicitly identifies the Comparator as Fluarix Quadrivalent, a standard-dose quadrivalent vaccine. Therefore, the quote genuinely supports the claim that Flublok (quadrivalent) was evaluated in the pivotal trial against Fluarix (quadrivalent standard-dose vaccine).",
      "original_relevance": "This quote explicitly states that Flublok Quadrivalent was compared to a 'Comparator' in Study 6, and that relative vaccine efficacy was calculated between Flublok Quadrivalent and the Comparator, directly supporting the claim that Flublok Quadrivalent was evaluated against another quadrivalent vaccine in a pivotal trial."
    },
    {
      "id": "comp_2",
      "quote": "Comparator, Fluarix Quadrivalent, manufactured by GlaxoSmithKline (n=4489). Among randomized subjects, 58% were female, 80% white, 18% black/African-American, other races, and 5% of Hispanic/Latino ethnicity. A total of 5186 (60%) subjects w",
      "supports_claim": true,
      "explanation": "The quote appears on page 4 of the document: 'mpa rat or, Fluarix Quad rival ent, manufactured by Glaxo Smith kline) (n 4489). ong randomized subjects, 58% were female, 80% white, 18% black/African-Ameri other races, and 5% of Hispanic/Latino ethnicity. A total of 5186 (60%) subjects w'. This matches the quoted content in terms of meaning, numbers, and technical content, despite minor OCR artifacts and word breaks.. The quote explicitly identifies the comparator in the pivotal trial as Fluarix Quadrivalent, manufactured by GlaxoSmithKline, and provides demographic data for the randomized subjects. This directly supports the claim that Flublok (quadrivalent) was evaluated in the pivotal trial against Fluarix (quadrivalent standard-dose vaccine).",
      "presence_explanation": "The quote appears on page 4 of the document: 'mpa rat or, Fluarix Quad rival ent, manufactured by Glaxo Smith kline) (n 4489). ong randomized subjects, 58% were female, 80% white, 18% black/African-Ameri other races, and 5% of Hispanic/Latino ethnicity. A total of 5186 (60%) subjects w'. This matches the quoted content in terms of meaning, numbers, and technical content, despite minor OCR artifacts and word breaks.",
      "support_explanation": "The quote explicitly identifies the comparator in the pivotal trial as Fluarix Quadrivalent, manufactured by GlaxoSmithKline, and provides demographic data for the randomized subjects. This directly supports the claim that Flublok (quadrivalent) was evaluated in the pivotal trial against Fluarix (quadrivalent standard-dose vaccine).",
      "original_relevance": "This quote identifies the Comparator in the study as Fluarix Quadrivalent, manufactured by GlaxoSmithKline, confirming that Flublok Quadrivalent was evaluated against Fluarix Quadrivalent in the pivotal trial."
    }
  ],
  "verification_stats": {
    "total_verified": 5
  },
  "image_evidence": [
    {
      "image_filename": "figure_p4_det_3_007.png",
      "image_path": "FlublokPI/extracted/figures/figure_p4_det_3_007.png",
      "image_type": "Figure",
      "page_number": 4,
      "block_id": "det_3_007",
      "claim_id": "claim_005",
      "claim": "Flublok (quadrivalent) was evaluated in the pivotal trial against Fluarix (quadrivalent standard-dose vaccine).",
      "supports_claim": true,
      "explanation": "A table summarizing influenza attack rates, relative risk (RR), and relative vaccine efficacy (rVE) comparing Flublok quadrivalent against a comparator. The footnote specifies the comparator as the U.S.-licensed influenza vaccine Fluarix Quadrivalent. Evidence: Footnote stating 'Comparator = U.S.-licensed influenza vaccine, Fluarix Quadrivalent' The table\u2019s footnote explicitly identifies Fluarix Quadrivalent as the comparator in the pivotal trial, which supports the claim Note: Image includes only part of the table and footnotes, but the comparator identification is clear",
      "model_used": "o4-mini",
      "detailed_analysis": {
        "supports_claim": true,
        "image_description": "A table summarizing influenza attack rates, relative risk (RR), and relative vaccine efficacy (rVE) comparing Flublok quadrivalent against a comparator. The footnote specifies the comparator as the U.S.-licensed influenza vaccine Fluarix Quadrivalent.",
        "evidence_found": "Footnote stating 'Comparator = U.S.-licensed influenza vaccine, Fluarix Quadrivalent'",
        "reasoning": "The table\u2019s footnote explicitly identifies Fluarix Quadrivalent as the comparator in the pivotal trial, which supports the claim",
        "confidence_notes": "Image includes only part of the table and footnotes, but the comparator identification is clear"
      }
    }
  ]
}